TickerFacts.

CASI Pharmaceuticals, Inc. (CASIF): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$20.77M
Year ended 2025-12-31
2020-12-31: -$27.39M2021-12-31: -$35.79M2022-12-31: -$26.70M2023-12-31: -$20.17M2024-12-31: -$29.45M2025-12-31: -$20.77M-$20.77M
2020-12-31 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31-$20.77Mn/m2026-05-15, From 2025-01-01
2024-12-31-$29.45Mn/m2026-05-15, From 2024-01-01
2023-12-31-$20.17Mn/m2026-05-15, From 2023-01-01
2022-12-31-$26.70Mn/m2025-03-31, From 2022-01-01
2021-12-31-$35.79Mn/m2024-03-28, From 2021-01-01
2020-12-31-$27.39Mn/a2023-04-26, From 2020-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
CASI Pharmaceuticals, Inc. (CASIF)2025-12-31-$20.77Mn/m
Evofem Biosciences, Inc. (EVFM)2025-12-31-$2.00Mn/m
Sol-Gel Technologies Ltd. (SLGL)2025-12-31$275.0Kn/m
NewAmsterdam Pharma Co N.V. (NAMS)2025-12-31-$148.03Mn/m
Alumis Inc. (ALMS)2025-12-31-$370.18Mn/m
Entrada Therapeutics, Inc. (TRDA)2025-12-31-$129.55Mn/m
Celularity Inc (CELU)2024-12-31-$6.56Mn/m
uniQure N.V. (QURE)2025-12-31-$178.40Mn/m
Cue Biopharma, Inc. (CUE)2025-12-31-$21.86Mn/m

Compare CASIF, EVFM, SLGL, NAMS side by side · Screen every company in Pharmaceutical Preparations ↗